Annovis Bio

ANVS

Market cap $45.8M

Overview Fund Activity

2.35 USD

+0.03

1.29%

At close Updated Sep 18, 4:00 PM EDT

1 day

1.29%

5 days

-2.08%

1 month

-12.64%

3 months

-12.96%

6 months

32.02%

Year to date

-54.01%

1 year

-71.89%

5 years

-55.91%

10 years

-75.5%

About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Employees: 6

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

26% more capital invested

Capital invested by funds: $3.13M [Q1] → $3.93M (+$802K) [Q2]

18% more call options, than puts

Call options by funds: $306K | Put options by funds: $260K

1.41% less ownership

Funds ownership: 10.71% [Q1] → 9.3% (-1.41%) [Q2]

5% less funds holding

Funds holding: 44 [Q1] → 42 (-2) [Q2]

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$10

326% upside

Avg. target

$10

326% upside

High target

$10

326% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Raghuram Selvaraju

$10

Buy

Maintained

3 Sep 2025

See Analyst Rankings

Financial journalist opinion

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of a new article in a peer-reviewed journal Biomolecules , which describes the pharmacokinetic (PK) profile of a new crystal form of buntanetap and compares it to the old form across several studies including mice, dogs, and humans.

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its CEO, Maria Maccecchini, Ph.D.

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results.

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families.

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Annovis to Attend the AAIC 2025 with Four Poster Presentations

MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards relating to minimum market capitalization and stockholders' equity.

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Zacks Investment Research

All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy

Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy

Annovis to Host Webinar and Live Q&A on June 24, 2025

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results.

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Annovis Bio Appoints Hui Liu as Director of Biostatistics

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics.

Annovis Bio Appoints Hui Liu as Director of Biostatistics

See News Rankings

Charts implemented using Lightweight Charts™